Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 27, 2022

Efficacy, Safety, and Immunogenicity of DNA SARS-CoV-2 Vaccine (ZyCoV-D)

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
Lancet 2022 Apr 02;399(10332)1313-1321, A Khobragade, S Bhate, V Ramaiah, S Deshpande, K Giri, H Phophle, P Supe, I Godara, R Revanna, R Nagarkar, J Sanmukhani, A Dey, TMC Rajanathan, K Kansagra, P Koradia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading